With EMA approval in December 2015, and US FDA approval in October 2015 of an oncolytic herpesvirus for the treatment of nonresectable melanoma, we now have a novel class of anticancer agents to add to our ever-promising arsenal of cancer (immuno-) therapeutics. Talimogen laherparapvec (T-VEC) therapy involves direct, intratumoral injection of a herpes simplex type 1 (HSV-1) virus which has bee...

Each year, twice as many people die in Europe from hospital acquired infections than from road accidents. These infectious diseases have developed antibiotic resistance and spread despite the best efforts of staff, mainly through textiles like bed linen. But the technology developed by a European research project helps fight back against the so-called superbugs, by using a revolutionary nanotec...